Hexarelin: The Strongest GH-Releasing Peptide — Power, Tolerance & Trade-offs
Hexarelin is a synthetic six-amino-acid peptide that ranks among the most powerful growth-hormone-releasing peptides ever studied: it hits the ghrelin receptor hard and drives a large, fast spike in growth hormone. The honest catch, and the reason this guide is framed around trade-offs, is that the body adapts to it. With repeated dosing, hexarelin's GH response fades, and at higher doses it spills over into cortisol and prolactin in a way cleaner peptides like ipamorelin avoid.
If you have seen hexarelin marketed as the "strongest GHRP," this guide is the high-level map of the whole compound: what it is, how it works on the ghrelin receptor, why it is so potent, the desensitization problem that defines it, its cortisol and prolactin trade-offs, its unusual heart effects, reported dosing, and its research-only legal status. Each section is a clear overview; the deep-dive comparisons and dosing ladders point to dedicated guides so this page stays a clean hub, and you can see where it sits among the best peptides for muscle growth.
Key Takeaways
- Hexarelin (examorelin) is a synthetic hexapeptide growth-hormone secretagogue (a GHRP) that works as an agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a), derived from GHRP-6 (Wikipedia, "Examorelin", retrieved 2026-06-15).
- It is one of the most potent GH-releasing peptides, with an ED50 for GH release of about 0.48 mcg/kg by intravenous injection in a 1996 dose-response study (Journal of Clinical Endocrinology & Metabolism, 1996).
- Its defining trade-off is desensitization. A 1998 study found the GH response fell by roughly 45% over 16 weeks of twice-daily use; Wikipedia summarizes a 50-75% drop in efficacy over weeks to months, partial and reversible after a break (Growth Hormone & IGF Research, 1998; Wikipedia, "Examorelin").
- It is less selective than ipamorelin. Acutely, an effective dose raised cortisol by about 40% and prolactin by about 180%, so higher doses are not "clean" GH (Journal of Clinical Endocrinology & Metabolism, 1996).
- It has growth-hormone-independent heart effects via the CD36 receptor, studied in animal heart-failure models for protective cardiac action (Turkish Journal of Medical Sciences, 2019).
- It is not FDA-approved and is banned in sport. Hexarelin never finished development past Phase II and appears on the WADA Prohibited List under class S2 (peptide hormones and growth factors) (Wikipedia, "Examorelin"; WADA Prohibited List, S2).
What is hexarelin?
Hexarelin is a synthetic peptide made of six amino acids that triggers the body to release its own growth hormone, by acting on the same receptor that the hunger hormone ghrelin uses. Its generic name is examorelin, and it belongs to a class called growth-hormone-releasing peptides, or GHRPs. It was developed in the early 1990s and studied for growth hormone deficiency and heart failure.
Chemically, hexarelin is a short chain with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, a molecular formula of C47H58N12O6, and a molar mass near 887 g/mol; its half-life is about 55 minutes (Wikipedia, "Examorelin", retrieved 2026-06-15). It was created by Mediolanum Farmaceutici as a more potent relative of the earlier peptide GHRP-6. Because it is a secretagogue, it does not add growth hormone to the body the way injecting synthetic GH does; instead it prompts the pituitary gland to release more of its own. If injectable peptides are new to you, start with our how peptides work guide.
The single most important fact about hexarelin is its status: it reached only Phase II clinical trials, was never marketed, and is not approved by any drug regulator for any use (Wikipedia, "Examorelin", retrieved 2026-06-15). It now exists in a small body of older research and, separately, in the unapproved "research chemical" market.
Citation capsule. Hexarelin (generic name examorelin) is a synthetic hexapeptide growth-hormone secretagogue and agonist of the ghrelin / GHS receptor, derived from GHRP-6, with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. It reached Phase II trials for GH deficiency and heart failure, was never marketed, and is not approved by any regulator. Source: Wikipedia, "Examorelin," 2026; CAS 140703-51-1; PubChem CID 6918297; ChEMBL CHEMBL108335; Wikidata Q21098927.
How does hexarelin work?
Hexarelin works by binding the ghrelin receptor (GHS-R1a) on the pituitary gland, which tells the gland to release a pulse of growth hormone. It uses the same receptor as the natural hunger hormone ghrelin, not the receptor that growth-hormone-releasing hormone (GHRH) uses. That difference is why GHRPs like hexarelin and GHRH analogs are sometimes combined: they push the same outcome through two separate doors.
In plain terms, hexarelin acts like a strong artificial "go" signal for the body's own growth-hormone release. When it binds GHS-R1a on the hormone-producing cells of the anterior pituitary, it sets off a cascade (inhibiting potassium channels, raising intracellular calcium) that ends in a pulse of growth hormone being secreted (JCSM Rapid Communications, "Growth hormone secretagogues: history, mechanism of action and clinical implications", 2020, retrieved 2026-06-15). This is the same family of mechanism behind ipamorelin, which is also a ghrelin-receptor agonist.
A crucial second target sets hexarelin apart. Beyond the pituitary, it also binds the CD36 scavenger receptor in cardiac tissue, which is thought to underlie heart effects that do not depend on growth hormone at all (Wikipedia, "Examorelin", retrieved 2026-06-15). We keep the receptor-and-signaling detail at overview level here and link out to how peptides work for the foundations.
How potent is hexarelin?
Hexarelin is one of the most potent growth-hormone-releasing peptides known, producing a large, fast GH spike at very small doses. In a 1996 human dose-response study, the dose needed to produce half of its maximum GH response (the ED50) was only about 0.48 mcg/kg by intravenous injection, and GH rose sharply from there. That is the kind of microgram-per-kilogram potency that earned hexarelin its "strongest GHRP" reputation.
The detail comes from a controlled dose-response study: researchers reported an ED50 for GH release of 0.48 plus or minus 0.02 mcg/kg, with GH climbing to a high plateau at the top doses (Journal of Clinical Endocrinology & Metabolism, "Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study", 1996, retrieved 2026-06-15). Hexarelin is generally described as producing GH pulses at least as large as its relatives GHRP-6 and GHRP-2, which is why it sits at the top of the potency conversation among GHRPs (JCSM Rapid Communications, 2020, retrieved 2026-06-15).
A practical nuance matters here, and it leads directly into the next two sections. Past a certain point, more hexarelin does not mean more growth hormone: the GH response saturates, so very large doses mostly add side effects rather than benefit. And, just as importantly, that strong initial response does not hold up over repeated dosing.
Our take: "Most potent GHRP" is true, but it is the least useful thing to know about hexarelin on its own. Raw potency is only valuable if the response lasts and stays selective. As the next two sections show, hexarelin loses on both counts, which is exactly why a weaker but cleaner peptide is often preferred for ongoing use.
Why does hexarelin stop working? The desensitization trade-off
Hexarelin's biggest weakness is desensitization: with continued use, the same dose releases less and less growth hormone, because the body adapts to the constant signal. This is the single most important practical fact about the compound. The good news is that the effect is partial and reversible: take a break, and the response largely returns.
The clearest evidence comes from a 1998 study in which twelve healthy older adults took hexarelin twice daily for 16 weeks. The growth-hormone response (measured as area under the curve) fell from about 19.1 at the start to 13.1 by week 1, 12.3 by week 4, and 10.5 by week 16, a roughly 45% decline (Growth Hormone & IGF Research, "Does desensitization to hexarelin occur during long term administration?", 1998, retrieved 2026-06-15). Wikipedia summarizes the human picture as "a partial and reversible tolerance to the GH-releasing effects of examorelin occurs in humans with long-term administration (50-75% decrease in efficacy over the course of weeks to months)" (Wikipedia, "Examorelin", retrieved 2026-06-15).
The response recovers after a break
The reversibility is the part that gives hexarelin a usable, if awkward, profile. In the same 1998 study, after subjects stopped hexarelin for four weeks, the GH response climbed back to about 19.4, statistically no different from where it started (Growth Hormone & IGF Research, 1998, retrieved 2026-06-15). In other words, the desensitization is the body turning the volume down on a signal that never stops, not permanent damage, and removing the signal lets it reset.
This is why the desensitization curve, not the potency number, should drive how anyone thinks about hexarelin. A peptide that is briefly the strongest but fades within weeks behaves very differently from one with a steadier, lower response. It is also why community protocols lean on short cycles and breaks rather than continuous use. The full cycling-and-recovery deep-dive is its own topic; we keep it at overview level here.
What are hexarelin's cortisol and prolactin trade-offs?
Hexarelin is not a "clean" growth-hormone peptide: at effective doses it also nudges up cortisol (a stress hormone) and prolactin, and higher doses make that spillover worse. This is the second half of the trade-off and the main reason a more selective peptide is often chosen instead. The effect is acute and dose-dependent, and there is reassuring news on the chronic side too.
In the 1996 dose-response study, an effective dose of hexarelin raised cortisol by roughly 40% and prolactin by roughly 180% above baseline, with both effects plateauing as the dose climbed (Journal of Clinical Endocrinology & Metabolism, 1996, retrieved 2026-06-15). This is the contrast with ipamorelin, which is prized precisely because it releases GH with minimal cortisol or prolactin. There is an important nuance, though: a 1999 study of 16 weeks of hexarelin found the response did not over-stimulate the stress axis over time, with cortisol output actually falling slightly and prolactin unchanged across the study (Clinical Endocrinology, "The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin", 1999, retrieved 2026-06-15).
So the honest summary is two-sided. The spillover into cortisol and prolactin is real and shows up acutely, especially as the dose rises, which makes hexarelin less selective than its cleaner cousins. But it does not appear to snowball into chronic stress-hormone elevation at studied regimens. That combination, real but not accumulating, is part of why hexarelin keeps a niche despite the desensitization problem.
Our take: The cortisol and prolactin spillover is the reason "just take more" backfires with hexarelin. Above the saturating dose you do not gain much extra growth hormone, but you do recruit more of the side effects. The selectivity gap versus ipamorelin is a feature of the molecule, not a dosing mistake you can fully tune out, and our hexarelin vs ipamorelin head-to-head lays out exactly how that trade plays out.
How does hexarelin compare to ipamorelin and CJC-1295?
Hexarelin, ipamorelin, and CJC-1295 all raise growth hormone, but they are not interchangeable: hexarelin is a potent-but-messy GHRP that desensitizes fast, ipamorelin is a gentler, cleaner GHRP, and CJC-1295 is a different class (a GHRH analog) that works through a separate receptor. Understanding which lever each one pulls is the key to telling them apart.
The cleanest way to hold them apart is by class and trade-off. Hexarelin and ipamorelin are both ghrelin-receptor agonists (GHRPs), but ipamorelin trades some of hexarelin's raw punch for selectivity, releasing GH with little cortisol or prolactin and far less desensitization concern. CJC-1295 is a CJC-1295 analog of growth-hormone-releasing hormone (GHRH), so it acts on the GHRH receptor rather than the ghrelin receptor, which is why a GHRP and a GHRH analog are sometimes paired (JCSM Rapid Communications, 2020, retrieved 2026-06-15). The same GHRH-analog logic applies to sermorelin, a shorter-acting GHRH peptide.
| Peptide | Class | Receptor | Relative GH potency | Cortisol / prolactin spillover | Desensitization concern |
|---|---|---|---|---|---|
| Hexarelin | GHRP (secretagogue) | Ghrelin receptor (GHS-R1a) | Very high | Notable, dose-dependent | High (fades over weeks) |
| Ipamorelin | GHRP (secretagogue) | Ghrelin receptor (GHS-R1a) | Moderate | Minimal (selective) | Lower |
| CJC-1295 | GHRH analog | GHRH receptor | Moderate, sustained | Minimal | Lower (different mechanism) |
This contrast is deliberately high-level to avoid overlapping the dedicated guides. The full head-to-head comparisons, including stacking a GHRP with a GHRH analog and how the two mechanisms add up, live in those articles: see ipamorelin, CJC-1295, and sermorelin.
Does hexarelin have effects on the heart?
Yes, and they are unusual: separate from its growth-hormone action, hexarelin appears to protect heart tissue directly through the CD36 receptor, an effect studied mostly in animals. This is the part of hexarelin's profile that has nothing to do with muscle or recovery and is the reason it was once explored as a heart-failure treatment.
In animal research, hexarelin has shown protective cardiac effects independent of growth hormone. In one 2019 rat study of heart failure, hexarelin improved the heart's pumping function, reduced chamber enlargement, fibrosis, and cell death, and modulated the PTEN and Akt/mTOR signaling pathways (Turkish Journal of Medical Sciences, "Modulation of PTEN by hexarelin attenuates cardiac dysfunction in heart failure rats", 2019, retrieved 2026-06-15). These effects are thought to run through the CD36 scavenger receptor in cardiac tissue rather than through the GH axis (Wikipedia, "Examorelin", retrieved 2026-06-15).
The honest caveat is that this is preclinical and historical: hexarelin reached Phase II trials for congestive heart failure but was never developed into an approved therapy (Wikipedia, "Examorelin", retrieved 2026-06-15). The cardiac story is interesting biology and part of why hexarelin remains a research curiosity, but it is not a basis for using an unapproved peptide for heart health.
What doses of hexarelin do people report using?
There is no validated dose for hexarelin, but reported research and community protocols cluster around 100 mcg per dose, given one to a few times a day, with the strong advice to keep doses small because the GH response saturates. These are figures people report, not an established or recommended dose, and there is no approved label to anchor them.
Reported community use most often describes about 100 mcg per subcutaneous dose, sometimes one to three times daily and spaced several hours apart, with the common warning that going much above roughly 100 to 200 mcg mostly adds cortisol and prolactin rather than more growth hormone (Peptides Institute, "Hexarelin", 2025, retrieved 2026-06-15). We label all of this as a community convention because no regulator has reviewed a dose; the only peer-reviewed dosing anchors are the microgram-per-kilogram intravenous figures from the 1996 dose-response work and the twice-daily regimen used in the 1998 desensitization study (Journal of Clinical Endocrinology & Metabolism, 1996; Growth Hormone & IGF Research, 1998, retrieved 2026-06-15).
For orientation only, here is how people commonly describe the reported use (not a recommendation):
| Reported parameter | Commonly reported figure | Notes |
|---|---|---|
| Per-dose amount | ~100 mcg subcutaneous | GH response saturates; more is not more GH |
| Frequency | 1-3x/day, spaced several hours | Often pre-bed and/or fasted |
| Higher doses | Above ~200 mcg | Disproportionately raise cortisol / prolactin |
| Cycling | Short cycles with breaks | To work around desensitization |
The detailed titration math, reconstitution volumes, and injection-site choices are dedicated topics. We cover only the high-level framing here and link out to the how peptides work foundations and the broader GH-axis guides.
How much does the ProtocolPlus community track hexarelin?
Hexarelin is a small, niche compound in the ProtocolPlus app: it accounts for roughly 0.6% of all logged doses, far behind the cleaner GH peptides, which lines up with its reputation as a powerful but high-maintenance option. This is a usage signal from our tracking community, not a measure of how well it works.
In the app's tracking window (September 2024 to June 2026), hexarelin has 240 tracking users and 1,500 logged doses, out of 233,668 logged doses across all 42 tracked compounds, about 0.64% of total dosing activity. For comparison, the more selective ipamorelin sees 5,400 logged doses and the GHRH-analog sermorelin 3,600, so within the GH-axis family hexarelin is the least-tracked of the group. Its reconstituted vials are typically finished quickly, in a median of about 17 days, consistent with the short, broken-up cycles people use to dodge desensitization. These figures are sourced from our canonical app dataset, rendered server-side so they sit in the crawlable page; they are a usage convention, not a clinical or stability claim.
What are the side effects of hexarelin?
Hexarelin's reported side effects fall into two buckets: the predictable hormone-related ones (cortisol, prolactin, water retention, hunger from ghrelin-receptor activation) and the unknowns that come with an unapproved, under-tested compound. "Under-tested in modern use" is the honest framing, not "safe."
Because hexarelin activates the ghrelin receptor, the most commonly reported effects mirror that biology and the hormone spillover discussed above. The clinical studies that exist were small and short by modern standards, so the long-term human safety picture is thin.
- Hormone-related: increased cortisol and prolactin at higher doses, plus the GH-driven effects like water retention, tingling, or joint aches that GH secretagogues can cause.
- Ghrelin-receptor effects: increased hunger and, for some, transient effects on blood sugar, since the ghrelin receptor sits at the crossroads of appetite and metabolism.
- Diminishing benefit: the desensitization itself is a practical downside, the response fades while exposure continues.
- Quality-related risks: because the market is unregulated, contamination, mislabeled potency, or impurities are real concerns independent of the peptide itself.
- Unknown: true long-term safety in humans, because modern long-horizon data simply do not exist for this older, never-marketed compound.
This is the hub-level summary. For the foundational safety framing that applies to every research peptide, see are peptides legal and our general peptide guides.
Is hexarelin safe and legal?
Hexarelin is not approved by any regulator, so there is no official safety determination, it cannot be legally prescribed or sold as a medicine, and it is banned in sport; the products sold online are unapproved "research chemicals." That status matters more than any single study.
On legality, hexarelin never completed development, so there is no approved version to prescribe: it reached Phase II trials and was never marketed (Wikipedia, "Examorelin", retrieved 2026-06-15). It is also banned in sport. Hexarelin (examorelin) falls under the World Anti-Doping Agency Prohibited List class S2, peptide hormones, growth factors, and related substances, where growth-hormone secretagogues and GHRPs are prohibited at all times, in and out of competition (WADA Prohibited List, S2, retrieved 2026-06-15). For the full legal picture and how to evaluate a vendor, see are peptides legal.
On safety, the older trial data looked manageable for a short-term investigational compound, but "tolerated in small, short studies" is not the same as "established safe," especially given the cortisol and prolactin spillover and the complete absence of modern long-term data. Using it means accepting unknown risks with no regulatory safety net.
Our take: The most common misunderstanding is that being sold openly online makes hexarelin legal and vetted. It is sold "for research use only," it is an unapproved drug that never made it to market, and it is explicitly banned in sport. Easy to buy is not the same as legal or safe.
The bottom line
Hexarelin is the clearest case study in the peptide world of why "strongest" is not the same as "best." It is genuinely one of the most potent growth-hormone-releasing peptides, it works through the ghrelin receptor, and it even has intriguing growth-hormone-independent effects on the heart. That power is real, and it is why hexarelin still gets talked about.
The other half of the story is the trade-off this guide is named for. The GH response desensitizes within weeks of continued use, recovering only after a break, and at the doses that release a lot of GH, hexarelin also spills over into cortisol and prolactin in a way the cleaner ipamorelin avoids. Add that it is unapproved, never marketed, banned in sport, and sold only as an unregulated research chemical, and the honest label is investigational. If you take one thing from this hub, let it be that a steadier, more selective peptide often beats a stronger one that fades, and that a qualified clinician is the right person to weigh any of this. From here, the natural next reads are ipamorelin, CJC-1295, and are peptides legal.
Frequently Asked Questions
Sources
- Wikipedia. "Examorelin." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Examorelin
- Massoud AF, Hindmarsh PC, Brook CG. "Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study." Journal of Clinical Endocrinology & Metabolism, 1996. PMID 8954038. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/8954038/
- Rahim A, Shalet SM. "Does desensitization to hexarelin occur during long term administration?" Growth Hormone & IGF Research, 1998. PMID 10990150. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/10990150/
- Rahim A, O'Neill PA, Shalet SM. "The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin." Clinical Endocrinology, 1999. PMID 10341859. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/10341859/
- Ishida J, et al. "Growth hormone secretagogues: history, mechanism of action and clinical implications." JCSM Rapid Communications, 2020. Retrieved 2026-06-15. https://onlinelibrary.wiley.com/doi/full/10.1002/rco2.9
- Agbo E, et al. "Modulation of PTEN by hexarelin attenuates cardiac dysfunction in heart failure rats." Turkish Journal of Medical Sciences / PMC, 2019. Retrieved 2026-06-15. https://pmc.ncbi.nlm.nih.gov/articles/PMC7018219/
- World Anti-Doping Agency. "S2. Peptide Hormones, Growth Factors, Related Substances and Mimetics" (Prohibited List). Retrieved 2026-06-15. https://www.drugs.com/wada/s2-peptide-hormones-growth-factors-and-related-substances.html
- Peptides Institute. "Hexarelin." 2025. Retrieved 2026-06-15. https://www.peptidesinstitute.org/peptides/hexarelin
- PubChem. "Examorelin, CID 6918297." Retrieved 2026-06-15. https://pubchem.ncbi.nlm.nih.gov/compound/6918297